Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-Chlorodeoxyadenosine: drug development priorities

L D Piro

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |October 1, 1992
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.

    Leukemia & lymphoma·2016
    Same author

    2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·1999
    Same author

    Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.

    Blood·1998
    Same author

    Reduced charges and costs associated with outpatient autologous stem cell transplantation.

    Bone marrow transplantation·1998
    Same author

    2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.

    Leukemia & lymphoma·1998
    Same journal

    Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles